Nexalin Technology (NXL) Fireside Chat

Oct 1, 2024

During this fireside we welcome Nexalin Technology. Nexalin (Nasdaq: NXL) designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.

This Fireside Chat was recorded during the Lytham Partners Fall 2024 Investor Conference.

Skip to content